Tag Archive for: HHT

RougeTx Launches with $58 Million Series A Financing to Advance First-in-Class Treatment for Hereditary Hemorrhagic Telangiectasia

  Series A co-led by BioGeneration Ventures, Angelini Ventures and Kurma Partners, with participation from Epidarex Capital, Vesalius Biocapital Partners, ROM Utrecht Region, p53 Invest and Kerna Ventures. Financing will advance a potential once-daily oral treatment designed to restore blood vessel stability in HHT, a serious inherited bleeding disorder with no approved therapies. periSCOPE platform […]

© Optimum Strategic Communications.